Kyntra Bio earnings beat by $3.77, revenue fell short of estimates

Kyntra Bio (KYNB) reported Q3 EPS of $0.04, beating estimates by $3.77, but revenue of $1.76M missed expectations of $1.83M. The stock is down 56.28% over 3 months and 63.22% over 12 months. InvestingPro rates its financial health as 'fair performance'.

Original reporting
Published Nov 16, 2026, 9:48 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 16, 2026, 10:18 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefEarnings
Primary signal
$KYNB
Neutral
medium confidence
Mentioned
$KYNB
Relevance
8/10
AlphAI data visualization · based on investing.com
Decision brief

The 30-second read

$KYNBNeutralMed
01

Why it matters

A large EPS beat alongside a modest revenue miss can produce volatility, especially for heavily de-risked small-cap names where expectations are fragile.

02

Market read

Traders get a fresh earnings datapoint (EPS and revenue vs estimates) that can drive near-term positioning and volatility.

03

What to watch

The article does not include guidance, cash burn, or balance-sheet details, which are often the real drivers for biotech post-earnings moves.

Relevance 8/10Novelty 7/10Timing: after-hours/next-session reaction to the just-reported Q3 results

Background

The piece summarizes Kyntra Bio’s Q3 results versus consensus and notes recent EPS revision activity and the stock’s recent drawdown.

Company-level read

Ticker impact

$KYNBNeutralMedium confidence
Context

Kyntra Bio reported Q3 EPS of $0.040 versus a $-3.730 estimate, while revenue was $1.76M versus $1.83M consensus.

Expected impact

Likely choppy trading, with upside bias from the large EPS beat offset by selling pressure tied to the revenue miss.

Evidence & confidence

The article provides both the EPS beat magnitude and the revenue miss versus consensus, which typically drives near-term repricing and guidance sensitivity.

Market effects

Limited spillover expected, as this is a single micro/small-cap biotech earnings print with no sector-wide catalyst described.

No clear regional macro linkage beyond general risk sentiment toward small-cap biotech earnings.

Minimal, since the article contains no international regulatory, trial, or partnership developments.

Counterpoint

The EPS beat may reflect accounting or one-off items, so traders may discount it if revenue weakness persists.

Key entities

  • Kyntra Bio

    NASDAQ-listed biotech reporting Q3 EPS and revenue versus analyst consensus.

Related articles

$KYNBMed

Kyntra Bio Reports Third Quarter 2026 Financial Results and Provides Business Update

KYNTRA BIO, INC. (KYNB) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Kyntra Bio Reports Third Quarter 2026 Financial Results and Provides Business Update • Completed restructuring of royalty financing agreement, reducing the maximum aggregate payment obligation by $60 million, with only $15 million in future royalty-backed payments re

$KYNBMed

Oppenheimer reiterates Kyntra Bio stock rating on debt reduction

Oppenheimer maintained an Outperform rating and $35.00 price target for Kyntra Bio (NASDAQ:KYNB) after the company restructured its royalty financing agreement, reducing obligations to $65M from $125M. The company made a $42.6M payment, eliminating $60M in future obligations while retaining royalty economics. Kyntra Bio has a current ratio of 2.69 and is trading at $7.78, below analyst targets. Oppenheimer expects Phase 3 and Phase 2 data in 2026 and sees improved financial flexibility.

$KYNBMedAI 8/10

Kyntra Bio (KYNB) Q2 2026 Earnings Call Transcript

Kyntra Bio (KYNB) reported Q2 2026 earnings with revenue of -$1.5M, net income of $12.0M, and $95.7M in cash. Clinical updates include FG-3246 Phase II enrollment and roxadustat Phase III plans. Management expects cash to last into 2028 and discussed potential partnerships for roxadustat.

$KYNBMedAI 8/10

Kyntra Bio (KYNB) Q2 2026 Earnings Call Transcript

Kyntra Bio (KYNB) reported Q2 2026 revenue of -$1.5M, a net income of $12.0M, and $95.7M in cash. Clinical trials for FG-3246 in prostate cancer and roxadustat in MDS showed progress. Operating expenses rose to $16.1M. Management expects cash to last into 2028 and is evaluating partnership options for roxadustat.

$KYNBMed

Kyntra Bio Reports Second Quarter 2026 Financial Results and Provides Business Update

KYNTRA BIO, INC. (KYNB) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Kyntra Bio Reports Second Quarter 2026 Financial Results and Provides Business Update • Phase 2 monotherapy trial of FG-3246, a potential first-in-class antibody drug conjugate (ADC) targeting CD46 in metastatic castration-resistant prostate cancer (mCRPC), continues